RESPONSE

OFFICIAL TITLE: PREDICTORS OF 18F-FDG PET-DRIVEN DISEASE DETECTION IN HER2+ EARLY BREAST CANCER PATIENTS. A SUB-STUDY OF THE PHERGAIN CLINICAL TRIAL

ESMO 2020 – DOWNLOAD THE POSTER

LIST OF AUTHORS AND COI's – DOWNLOAD

PROJECT DETAILS

THE RESPONSE PROJECT IS A SUB-STUDY OF THE PHERGAIN CLINICAL TRIAL, AIMING AT EXPLORING THE ASSOCIATION BETWEEN CLINICAL, MOLECULAR, AND METABOLIC TUMOR CHARACTERISTICS AND THE PROBABILITY OF DISEASE DETECTION BY 18F-FDG PET (PET) IN ALL THE HER2+ EARLY BREAST CANCER (EBC) PATIENTS SCREENED IN THE PHERGAIN TRIAL. AS INITIAL ESTIMATIONS ON SCREENING FAILURES PATIENTS BY PET (PET[-]) WERE UNDERESTIMATED, A SELECTED COHORT OF 21 PET[-] AND 21 PET[+] MATCHED PATIENTS FROM THE PHERGAIN TRIAL WERE EVALUATED WITH THE INTENTION OF ACHIEVING AN APPROPRIATE PATIENT SELECTION USING A RESPONSE-ADAPTED STRATEGY IN THE HER2+ EBC.

TUMOR TYPE

PHASE

N

SITES

COUNTRY

STATUS

BREAST

Sub-study

377 

patients included in the PHERGain study; selected cohort of 21 PET[-] and 21 PET[+] matched patients

56

Spain, Portugal, France,

UK, Italy, Belgium,

Germany

Analysis performed